(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 December 2018 (13.12.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/226560 A1

(51) International Patent Classification:
C12N 9/10 (2006.01)

(21) International Application Number:
PCT/US2018/035806

(22) International Filing Date:
04 June 2018 (04.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/515,140	05 June 2017 (05.06.2017)	US
62/550,161	25 August 2017 (25.08.2017)	US
62/659,344	18 April 2018 (18.04.2018)	US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **UNIVERSITY OF MARYLAND, BALTIMORE** [US/US]; 620 W. Lexington Street, 4th Floor, Baltimore, MD 21202 (US).

(72) Inventors: **MONTASSER, May**; 305 West Fayette Street, Apartment 1411, Baltimore, MD 21201 (US). **VAN HOUT, Cristopher**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **SHULDINER, Alan**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **GATTA, Giusy, Della**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **HEALY, Matthew**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **PUURUNEN, Marja**; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **LEGAARD, Paul, K.**; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, PA 19355-1481 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2018/226560 A1

(54) Title: *B4GALT1* VARIANTS AND USES THEREOF

(57) Abstract: Variant *B4GALT1* genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous *B4GALT1* genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant *B4GALT1* genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.